PharmaEssentia (6446) Q3 2024 earnings summary

Executive summary

• Achieved strong revenue growth and returned to profitability for the nine months ended September 30, 2024, compared to a net loss in the prior year period.

• Significant increase in operating revenue, driven by higher sales of medicine products and expansion in international markets.

• Raised substantial capital through a global depository share (GDS) issuance and continued investment in R&D and production capacity.

Financial highlights

• Operating revenue for the nine months ended September 30, 2024 was NTD 6,673,280 thousand, up from NTD 3,458,760 thousand year-over-year.

• Net income for the nine months was NTD 1,729,897 thousand, compared to a net loss of NTD 739,772 thousand in the same period last year.

• Basic EPS for the nine months was NTD 5.23, versus a loss per share of NTD 2.31 year-over-year.

• Gross margin improved to 88% for the nine months, up from 90% in the prior year period.

• Cash and cash equivalents increased to NTD 20,831,816 thousand as of September 30, 2024.

Outlook and guidance

• Continued focus on expanding global market presence and advancing clinical trials for new indications.

• Ongoing investments in production capacity, including new plant construction and additional production lines.